source
- Moderna and Merck aim to file personalized cancer vaccine for FDA approval after Phase 3 successModerna CEO Stéphane Bancel said the company’s personalized cancer vaccine, intismeran, met its primary goals in a pivotal Phase 3 trial. The success was disclosed during an interview at the ESMO m…
- Taysha and Neurogene close in on first Rett syndrome gene therapy as 2027 readouts loomTwo companies, Taysha Gene Therapies and Neurogene, are nearing the final stage of development for gene therapies targeting Rett syndrome, a rare neurodevelopmental disorder with limited treatment…